



Using evidence based medicine when choosing a joint supplement?

Parnell's GLYDE™ mobility chews are veterinary nutraceuticals with strong scientific backing.

Evidence based medicine is a key aspect of veterinary medicine. As veterinary advice experts, veterinarians expect that all product claims have been substantiated through scientific evidence. Unfortunately, veterinary nutraceuticals are not closely regulated, thus leaving many products open to poor quality control and misleading labeling.¹

The American Veterinary Medical Association has defined nutraceutical medicine as "the use of micronutrients, macronutrients, and other nutritional supplements as therapeutic agents".² The nutraceutical movement is rapidly growing and gaining popularity within the human and veterinary markets. Pet parents are increasingly seeking information on how to introduce nutraceutical medicine into the daily treatment of their pets. Professional bodies such as the AAHA and AAEP are offering advice on integration of nutraceuticals into treatment paradigms.³

At Parnell, we take veterinary pharmaceuticals and veterinary nutraceuticals seriously and this is why we developed Glyde Mobility Chews for treatment of osteoarthritis (OA). Unlike many of the products on the nutraceutical market, we produce our product within facilities that are compliant with Good Manufacturing Practices (GMP) and have a US NASC Preferred Supplier seal. This measure helps us maintain and assure a high level of quality control within our product manufacturing.

Glyde Mobility Chews contain three active ingredients that contribute to their efficacy. These three ingredients that provide cartilage building blocks are glucosamine, chondroitin and green lipped mussel (GLM) powder. GLM also provides strong anti-inflammatory activity and has been shown to reduce and repair damage to cartilage. All three ingredients have been scientifically proven to be effective at controlling the signs of osteoarthritis, slowing disease progression and restoring the health of the joint.

It is well known that glucosamine and chondroitin are considered the main building blocks to maintaining a healthy joint. These two compounds have been the basis of many joint supplements and have withstood the test of time. Many scientific studies have been performed on these compounds, both individually and in combination, with statistically significant improvements in signs of OA in dogs.^{4,5,6}



THE Science Behind GLYDE

Glucosamine HCL

- Reduces pain, improves joint function and mobility and reduces OA progression¹⁷
- Inhibits cartilage degradation¹⁵
- Reduces joint space narrowing in the knee¹²
- Precursor of glycosaminoglycan production⁹
- Stimulates glycosaminoglycan synthesis⁶
- Increases proteoglycan production¹¹
- Suppresses neutrophilic inflammation¹⁰
- Good bioavailability and absorption¹²

Chondroitin Sulfate

- Reduces pain, improves joint function and mobility and reduces OA progression¹⁷
- Inhibits synovial membrane inflammation¹⁶
- Predominant glycosaminoglycan use by chondrocytes to produce proteoglycans¹⁴
- Stimulates glycosaminoglycan synthesis⁶
- Maintains viscosity of synovial fluid^{18,26}
- Good bioavailability and absorption¹²

Green-Lipped Mussel

- Significant improvement in clinical signs of osteoarthritis²⁰
- Protects against induced arthritis and reverses existing inflammation^{19,22}
- Reduces joint pain and swelling²⁰
- Improved force plate measurements²¹
- Results in increased plasma omega-3 fatty acids²¹
- Potent anti-inflammatory activity^{22,13,23,24,25}



The data for human use is also very strong, and the European League Against Rheumatism (EULAR) rated Glucosamine and Chondroitin in their guidelines for human knee OA with the highest evidence grade and the highest recommendation strength. It is therefore possible to use glucosamine and chondroitin in dogs with confidence that they are effective.

Green lipped mussel is known to be very high in omega-3 and other fatty acids and provides a strong, natural anti-inflammatory effect to the joint.⁷ When analyzed, GLM was found to contain glycosaminoglycans, amino acids, omega-3 fatty acids including docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and eicosatetraenoic acid (ETA), zinc, copper, manganese as well as vitamins A, D3, E and B12^{8,13}. The concentration of New Zealand green-lipped mussel found in our chews is higher than that used in studies demonstrating efficacy in dogs with osteoarthritis. When added to the glucosamine and chondroitin, GLM creates a well-rounded supplement that targets the OA disease itself as well as secondary pain and inflammation.

When considering adding an OA joint supplement to your product line, I strongly recommend you consider Glyde. This product, available through licensed veterinarians, is well received by vets and pet parents alike. Pet parents particularly appreciate the attention to detail that is demonstrated by the heart shaped chew.



1. Adebowale A, Cox D, Liang Z, et al. Analysis of glucosamine and chondroitin sulfate content in marketed products and the Caco-2 permeability of chondroitin sulfate raw materials. *JANA* 2000;3:37-44.
2. American Veterinary Medical Association. Guidelines for alternative and complementary veterinary medicine. In: 1999 AVMA Directory and Resource Manual, 48th ed. Schaumburg, Illinois: American Veterinary Medical Association.
3. 2007 AAHA/AAFP Pain Management Guidelines for Dogs and Cats https://www.aaha.org/professional/resources/pain_management_2007.aspx
4. Canapp S, McLaghlin R, Hoskinson J, et al. Scintigraphic evaluation of glucosamine HCL and chondroitin sulfate as treatment for acute synovitis in dogs. *AJVR* 1999;60(12):1552-7.
5. McCarthy G, O'Donovan J, Jones B, et al. Randomised double-blind, positive-controlled trial to assess the efficacy of glucosamine/chondroitin sulfate for the treatment of dogs with osteoarthritis. *The Vet J* 2007;174:54-61.
6. Lippiello L, Woodward J, Karpman R, Hammand T. In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate. *Clinical Orthopaedics and Related Research* 2000;381:229-240.
7. Brien S, Prescott P, Coghlan B, et al. Systemic review of the nutritional supplement Perna Canaliculus (green-lipped mussel) in the treatment of osteoarthritis. *Q J Med*;101:167-179.
8. Rialland P, Bichot S, Lussier B, et al. Effect of a diet enriched with green-lipped mussel on pain behavior and functioning in dogs with clinical osteoarthritis. *Can J Vet Res* 2013;77:66-74
9. Davidson G. Glucosamine and Chondroitin Sulfate. *Compend Contin Educ Prac Vet* 2000;22(5):454-458.
10. Hua J, Sakamoto K, Nagaoka I. Inhibitory actions of glucosamine, a therapeutic agent for osteoarthritis, on the functions of neutrophils. *J Leuk Bio* 2002;71:632-640.
11. Bassleer C, Rovati L, Franchimont P. Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro. *Osteoarthritis and Cartilage*. 1998;6:427-434.
12. Henroitin Y, Sanches C, Balligand M. Pharmaceutical and nutraceutical management of canine osteoarthritis: present and future perspectives. *Vet J*. 2005;170(1):113-123.
13. Coulson S, Palacios T and Vitetta L. Perna canaliculus (Green-Lipped Mussel): Bioactive Components and Therapeutic Evaluation for Chronic Health Conditions. *Progress in Drug Research*. 2015;70:91-132
14. Beale BS: Use of nutraceuticals and chondroprotectants in osteoarthritic dogs and cats. *Vet Clin North Am Small Anim Pract* 34:271-289, 2004.
15. Dodge G, Jiminex S. Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritic articular chondrocytes. *Osteoarthritis and Cartilage*. 2003;11(6):424-432.
16. Henroitin Y, Lambert C, Richette P. Importance of synovitis in osteoarthritis: evidence for the use of glycosaminoglycans against synovial inflammation. *Semin Arthritis Rheum*. 2014;43(5):579-87
17. Jerosch J. Effects of Glucosamine and Chondroitin Sulfate on Cartilage Metabolism in OA: Outlook on Other Nutrient Partners Especially Omega-3 Fatty Acids. *Int J Rheumatol*. 2011;Epub 2011 Aug 2.
18. Tio L, Orellana C, Pérez-García S, Piqueras L, Escudero P, Juarranz Y, García-Giralt N, Montañés F, Farran A, Benito P, Gomariz RP, Sanz MJ, Monfort J. Effect of chondroitin sulphate on synovitis of knee osteoarthritic patients. *Med Clin (Barc)*. 2017 Feb 25. [Epub ahead of print].
19. Kendall RV, Lawson JW, Hurley LA. New research and a clinical report on the use of Perna canaliculus in the management of arthritis. *Townsend Letter for Doctors and Patients* July 2000;99-111.
20. Bierer TL, Bui LM. Improvement of Arthritic Signs in Dogs Fed Green-Lipped Mussel (Perna canaliculus). *J. Nutr.* 2002;132:16345-16365.
21. Rialland P, Bichoy S, Lussier B, et al. Effect of a diet enriched with green-lipped mussel on pain behavior and functioning in dogs with clinical osteoarthritis. *Can J Vet Res* 2013;77:66-74.
22. Lawson BR, Belkowski SM, Whitesides JF, Davis P, Lawson JW. Immunomodulation of murine collagen-induced arthritis by N,N-dimethylglycine and a preparation of Perna canaliculus. *BMC Complementary and Alternative Medicine* 2007;7:20.
23. Miller TE, Dodd J, Ormrod DJ, Geddes R, Wakimoto. Anti-inflammatory activity of glycogen extracted from Perna canaliculus (NZ green-lipped mussel). *Agents Actions*. 1993;38 Spec No:C139-42.
24. Lee CH, Butt YK, Wong MS, Lo SC. A lipid extract of Perna canaliculus affects the expression of pro-inflammatory cytokines in a rat adjuvant-induced arthritis model. *Eur Ann Allergy Clin Immunol*. 2008 Dec;40(4):148-53.
25. Kosuge T, Tsuji K, Ishida H, Yamaguchi T. Isolation of an anti-histaminic substance from green-lipped mussel (Perna canaliculus). *Chem Pharm Bull (Tokyo)*. 1986 Nov;34(11):4825-8.
26. David-Raoufi M, Deschrevel B, Leclercq S, Galéra P, Boumediene K, Pujol JP. Chondroitin sulfate increases hyaluronan production by human synoviocytes through differential regulation of hyaluronan synthases: Role of p38 and Akt. *Arthritis Rheum*. 2009 Mar;60(3):760-70.

